Merozoite surface protein 1 (MSP1) (PfMSP1)

Merozoite surface protein 1 (MSP1) is a large, essential glycoprotein expressed on the surface of Plasmodium falciparum merozoites, the stage of the malaria parasite that infects red blood cells (UniProt: P04932). It is synthesized as a 195 kDa precursor and undergoes primary proteolytic cleavage into four fragments (83, 30, 38, and 42 kDa) that remain associated on the merozoite surface. The C-terminal 42 kDa fragment (MSP1-42) undergoes a secondary cleavage by the protease SUB1 just prior to erythrocyte invasion, yielding a 33 kDa fragment and a 19 kDa fragment (MSP1-19). MSP1-19 remains attached to the parasite via a glycosylphosphatidylinositol (GPI) anchor and is the only part of the complex that enters the host cell (PMID: 10666295). Due to its critical role in invasion and its relatively conserved nature compared to other MSP1 regions, MSP1-42 and MSP1-19 are primary targets for blood-stage malaria vaccines. Therapeutic strategies focus on inducing antibodies that either prevent the secondary cleavage of MSP1-42 or physically block the interaction between MSP1-19 and the erythrocyte membrane (PMID: 15567784). However, the high degree of genetic polymorphism in the MSP1 gene across different parasite strains remains a significant hurdle for achieving broad vaccine efficacy (PMID: 17030517). Clinical trials have evaluated various formulations of MSP1-42 and MSP1-19, often in combination with potent adjuvants to enhance immunogenicity. Despite challenges with strain-specific immunity, MSP1 remains a cornerstone of research into multi-stage malaria vaccines.

Other names

MSP-1p190Polymorphic schizont antigenMSA-1MSP1-42MSP1-19Merozoite surface antigen 1PfMSP119

Induction of neutralizing antibodies that inhibit the proteolytic processing of MSP1-42 into MSP1-33 and MSP1-19, or block the interaction between MSP1-19 and the erythrocyte membrane, thereby preventing parasite entry into red blood cells (PMID: 10666295).